Ind-Swift Laboratories Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Ind-Swift Laboratories.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Nov 20

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Oct 20

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

Jul 02

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Apr 13

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Dec 28

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Jul 22

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Jul 12

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Feb 17

We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

Dec 30

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Nov 11

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Jun 27

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Ind-Swift Laboratories no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:INDSWFTLAB - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	7,423	3,734	-3,200	-2,851	N/A
6/30/2024	10,037	4,047	N/A	N/A	N/A
3/31/2024	12,973	4,210	-2,076	-1,631	N/A
12/31/2023	12,004	432	N/A	N/A	N/A
9/30/2023	12,256	513	2,002	2,153	N/A
6/30/2023	12,375	450	N/A	N/A	N/A
3/31/2023	12,159	476	1,818	1,946	N/A
12/31/2022	12,231	113	N/A	N/A	N/A
9/30/2022	11,571	-2	1,299	1,458	N/A
6/30/2022	10,691	-11	N/A	N/A	N/A
3/31/2022	10,529	-21	1,319	1,503	N/A
12/31/2021	9,754	301	N/A	N/A	N/A
9/30/2021	9,555	256	1,529	1,625	N/A
6/30/2021	9,536	111	N/A	N/A	N/A
3/31/2021	9,068	-31	1,306	1,349	N/A
12/31/2020	8,776	277	N/A	N/A	N/A
9/30/2020	8,536	77	1,110	1,224	N/A
6/30/2020	8,360	-111	N/A	N/A	N/A
3/31/2020	7,993	-212	1,141	1,252	N/A
12/31/2019	7,977	-734	N/A	N/A	N/A
9/30/2019	7,992	-211	1,314	1,406	N/A
6/30/2019	7,872	-35	N/A	N/A	N/A
3/31/2019	7,790	289	-798	-644	N/A
3/31/2018	7,769	220	N/A	731	N/A
3/31/2017	7,142	-391	N/A	956	N/A
3/31/2016	6,641	-587	N/A	794	N/A
3/31/2015	6,778	-1,194	N/A	984	N/A
3/31/2014	9,738	-1,220	N/A	655	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de INDSWFTLAB es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de INDSWFTLAB crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de INDSWFTLAB crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de INDSWFTLAB crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de INDSWFTLAB crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de INDSWFTLAB se prevé que sea elevada dentro de 3 años.

Ind-Swift Laboratories Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Second quarter 2025 earnings released: EPS: ₹0.07 (vs ₹5.36 in 2Q 2024)

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Chief Financial Officer recently sold ₹4.2m worth of stock

Ind-Swift Laboratories Limited to Report Q3, 2025 Results on Feb 14, 2025

Investor sentiment deteriorates as stock falls 21%

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹2.92 in 1Q 2024)

Ind-Swift Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

Investor sentiment improves as stock rises 24%

Ind-Swift Laboratories Limited Appoints Mr. Param Bir Singh as an Independent Director

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

New minor risk - Share price stability

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Full year 2024 earnings released: EPS: ₹71.24 (vs ₹8.06 in FY 2023)

New minor risk - Share price stability

Ind-Swift Laboratories Limited to Report Q4, 2024 Results on May 13, 2024

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 15%

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Essix Biosciences Limited.

Third quarter 2024 earnings released: EPS: ₹3.29 (vs ₹4.65 in 3Q 2023)

Ind-Swift Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Second quarter 2024 earnings released: EPS: ₹5.36 (vs ₹4.29 in 2Q 2023)

Ind-Swift Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: EPS: ₹2.92 (vs ₹3.36 in 1Q 2023)

Ind-Swift Laboratories Limited to Report Q1, 2024 Results on Aug 09, 2023

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Group Head of Human Resources recently sold ₹3.3m worth of stock

Investor sentiment improves as stock rises 16%

Chief Accounts Officer recently sold ₹1.6m worth of stock

Full year 2023 earnings released: EPS: ₹8.06 (vs ₹0.36 loss in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: ₹4.65 (vs ₹2.71 in 3Q 2022)

Insider recently sold ₹1.2m worth of stock

Second quarter 2023 earnings released: EPS: ₹4.29 (vs ₹4.14 in 2Q 2022)

Insider recently sold ₹1.6m worth of stock

Ind-Swift Laboratories Limited to Report Fiscal Year 2023 Results on May 30, 2023

First quarter 2023 earnings released: EPS: ₹3.36 (vs ₹3.18 in 1Q 2022)

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2022

Ind-Swift Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: ₹0.36 loss per share (vs ₹0.53 loss in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹4.14 (vs ₹1.68 in 2Q 2021)

Investor sentiment deteriorated over the past week

Soft Air General Trading LLC agreed to acquire Ind-Swift Middle East FZ-LLC from Ind-Swift Laboratories Limited (BSE:532305) for approximately $2 million.

First quarter 2022 earnings released: EPS ₹3.18 (vs ₹0.77 in 1Q 2021)

High number of new directors

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings released: ₹0.53 loss per share (vs ₹4.28 loss in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insider recently sold ₹1.0m worth of stock

Independent Director has left the company

Insider recently sold ₹1.4m worth of stock

Investor sentiment improved over the past week

Insider recently sold ₹2.1m worth of stock

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Third quarter 2021 earnings released: EPS ₹1.95 (vs ₹1.90 loss in 3Q 2020)

Ind-Swift Laboratories Limited to Report Q3, 2021 Results on Feb 12, 2021

Investor sentiment deteriorated over the past week

Ind-Swift Labs' Promoters Reportedly Sound Out PEs to Sell Their Stake

Senior Vice President of Procurement recently sold ₹2.7m worth of stock

New 90-day high: ₹72.00

Investor sentiment improved over the past week

We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings